Rapport Therapeutics (RAPP) Other financing activities (2024 - 2026)

Rapport Therapeutics (RAPP) has reported Other financing activities for 3 consecutive years, with $273000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 4450.0% year-over-year to $273000.0; the TTM figure through Mar 2026 stood at $1.6 million (changed N/A YoY), while the FY2025 annual figure was $1.3 million, up 19157.14% from the prior year.
• Other financing activities retreated to $273000.0 in Q1 2026 per RAPP's latest filing, from $706000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $706000.0 in Q4 2025 and bottomed at $6000.0 in Q1 2025.
• Historically, Other financing activities has averaged $380800.0 across 3 years, with a median of $283000.0 in 2024.
• Annual changes were most pronounced in 2025 — Other financing activities plunged 97.88% — and 2026, when it soared 4450.0%.
• Rapport Therapeutics' Other financing activities stood at $283000.0 in 2024, then soared by 149.47% to $706000.0 in 2025, then plunged by 61.33% to $273000.0 in 2026.
• Business Quant data shows RAPP's Other financing activities at $273000.0 in Q1 2026, $706000.0 in Q4 2025, and $636000.0 in Q3 2025.